logo

For the Inventor, By the Inventor

Wülfrath, Germany

Klaus Münter

This inventor holds 15 USPTO granted patents and 2 published patent applications and 11 EPO patents. Top assignees: Bayer Intellectual Property Gmbh, Bayer Healthcare Aktiengesellschaft, Bayer Pharma Aktiengesellschaft. Active years: 2006-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus Münter. Retrieved from https://idiyas.com/inventor/klaus-münter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 

% Patents Active = 33.3

 

Average Co-Inventor Count = 9.9

ph-index = 6

Forward Citations = 205(Granted Patents)


Location History:

  • Mülfrath, DE (2013)
  • Wülfrath, DE (2006 - 2019)

Company Filing History:

goldMedal7 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
silverMedal3 out of 77 
 
Bayer Healthcare Aktiengesellschaft
 patents
bronzeMedal2 out of 387 
 
Bayer Pharma Aktiengesellschaft
 patents
4. 2 out of 192 
 
Bayer Schering Pharma Ag
 patents
5. 1 out of 12,268 
 
Bayer Aktiengesellschaft
 patents
6. 1 out of 1 
 
Bayer Schering Pharma Aktiengellschaft
 patent
where one patent can have more than one assignee

Years Active: 2006-2019

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 10519154 - 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof (2019-12-31),
2. 10435403 - Positive allosteric modulators of muscarinic M2 receptor (2019-10-08),
3. 9051316 - Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use (2015-06-09),
4. 8987256 - Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof (2015-03-24),
5. 8487111 - Substituted oxazolidinones and their use (2013-07-16),
6. 8436180 - Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof (2013-05-07),
7. 8404709 - Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof (2013-03-26),
8. 8399471 - Aryl-or heteroaryl-substituted pyrido[2,3-d] pyrimidines and pharmaceutical compositions of the same (2013-03-19),
9. 8329716 - Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors (2012-12-11),
10. 7998988 - Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders (2011-08-16),
11. 7737153 - Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors (2010-06-15),
12. 7723347 - Substituted phenylamino-pyrimidines (2010-05-25),
13. 7498460 - Isophthalic acid derivatives (2009-03-03),
14. 7173037 - Carbamate-substituted pyrazolopyridines (2007-02-06),
15. 7135474 - Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators (2006-11-14),

Title: Klaus Münter: Innovator in Medicinal Chemistry

Introduction

Klaus Münter is a distinguished inventor based in Wülfrath, Germany, known for his significant contributions to medicinal chemistry. With a total of 15 patents to his name, he has made remarkable advancements in the field, particularly in the development of novel compounds for the treatment of various diseases.

Latest Patents

Münter's latest patents include innovative compounds such as 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides. This application relates to novel compounds that are utilized for the treatment and prevention of diseases, especially cardiovascular and renal disorders. Another notable patent is focused on positive allosteric modulators of the muscarinic M2 receptor, which also aims to address cardiovascular and renal disorders through novel 7-substituted 1-arylnaphthyridine-3-carboxamides.

Career Highlights

Throughout his career, Klaus Münter has worked with prominent companies in the pharmaceutical industry, including Bayer Intellectual Property GmbH and Bayer Healthcare Aktiengesellschaft. His work has been instrumental in advancing the understanding and treatment of complex medical conditions.

Collaborations

Münter has collaborated with esteemed colleagues such as Johannes-Peter Stasch and Karl-Heinz Schlemmer, contributing to a rich exchange of ideas and innovations in the field of medicinal chemistry.

Conclusion

Klaus Münter's contributions to medicinal chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to pave the way for advancements in the treatment of critical health issues.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…